Tag: BioNTech

The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving ...

The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for ...

The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a ...

Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races ...

The era of pandemic-era blockbuster revenues at BioNTech has come to a definitive end. The Mainz-based biotech is shuttering four ...

The first half of May is shaping up as a critical inflection point for BioNTech, with the German biotech facing ...

The narrative around BioNTech has shifted decisively. The pandemic-era cash cow is fading, and the company is now racing to ...

The German biotech has clawed back more than 22 percent from its March nadir of €72.50, closing Friday at €88.75. ...

The rally in BioNTech shares this month has been one of the sector's standout stories, but a hefty insider sale ...

The narrative around BioNTech is undergoing a quiet but decisive shift. While the Mainz-based biotech’s legacy COVID-19 vaccine business sputters, ...